BCPC Company Profile and Key Details

Q: Who are the executives of BCPC?

Mr. Mark A. StachExecutive OfficerMr. Jonathan GriffinSenior Vice President and GM of Animal Nutrition & HealthMr. Theodore L. HarrisChairman, Chief Executive Officer & PresMr. Frederic BonedSenior Vice President and GM of Human Nutrition & HealthMr. Brent TignorSenior Vice President & Chief HR OfficerMr. Jonathan H. GriffinSenior Vice President and GM of Animal Nutrition & HealthMr. Martin Luther ReidSenior Vice President & Chief Supply Chain OfficerMr. Carl Martin BengtssonExecutive Vice President, Chief Financial Officer & TreasurerMs. Hatsuki MiyataExecutive Vice President, Gen. Counsel & Corporation Sec.Mr. William A. Backus C.P.A., CPAVice President & CAOMr. William A. Backus CPA, CPAVice President & CAOMr. Michael R. Sestrick Ph.D.Senior Vice President & Chief Technology OfficerMr. Job L. van GunsterenSenior Vice President & GM of Specialty Products

NASDAQ : BCPC

Balchem

$180.29

0.67+0.37%

At Close 4:00 PM

73.24

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Balchem Corporation (BCPC) stock surged +0.37%, trading at $180.29 on NASDAQ, up from the previous close of $179.62. The stock opened at $180.00, fluctuating between $177.37 and $181.35 in the recent session.

Stock Snapshot

179.62

Prev. Close

5.84B

Market Cap

177.365

Day Low

39.45

P/E Ratio

4.57

EPS (TTM)

4.52

Cash Flow per Share

180

Open

32.39M

Number of Shares

181.3504

Day High

99.47%

Free Float in %

32.68

Book Value

133.68K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 26, 2026	179.45	181.35	177.37	180.29	139.91K
Feb 25, 2026	179.45	179.87	177.19	179.62	118.92K
Feb 24, 2026	175.00	179.11	173.00	178.56	197.92K
Feb 23, 2026	172.82	178.51	171.50	175.68	229.39K
Feb 20, 2026	174.53	175.00	167.19	171.30	184.36K
Feb 19, 2026	176.26	179.62	173.41	175.00	136.79K
Feb 18, 2026	179.55	180.91	176.36	177.50	149.25K
Feb 17, 2026	180.07	183.01	178.84	179.50	231.3K
Feb 13, 2026	177.10	181.17	176.65	180.81	224.95K
Feb 12, 2026	178.56	182.42	177.06	177.49	142.18K
Feb 11, 2026	174.69	179.20	173.23	178.68	195.84K
Feb 10, 2026	171.76	175.47	169.73	174.59	168.69K
Feb 09, 2026	172.60	174.01	171.07	172.29	203.05K
Feb 06, 2026	174.98	176.40	173.13	173.16	146.38K
Feb 05, 2026	174.27	175.90	172.19	173.72	158.41K
Feb 04, 2026	171.79	176.35	171.79	174.01	109.71K
Feb 03, 2026	170.51	172.19	168.90	170.80	171.41K
Feb 02, 2026	170.72	172.46	168.86	171.35	130.04K
Jan 30, 2026	170.25	170.67	167.80	170.17	178.94K
Jan 29, 2026	168.68	171.33	167.83	170.76	175.51K

Contact Details

Montvale, NY 10958

United States

https://www.balchem.com 845 326 5600

About Company

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.

Stock Peers

LIN

-9.76-1.92%

Linde plc$498.51 WDFC

-3.57-1.45%

WD-40 Company$242.15 HWKN

2.85999+1.95%

Hawkins, Inc.$149.49 SOLS

-1.55-1.94%

Solstice Advanced Materials Inc.$78.32 IOSP

-0.57-0.73%

Innospec Inc.$77.58 GPRE

0.25+1.79%

Green Plains Inc.$14.20 ADUR

0.25+2.16%

Aduro Clean Technologies Inc.$11.83 NTIC

0.11+1.26%

Northern Technologies International Corporation$8.87 HDSN

-0.03000021-0.42%

Hudson Technologies, Inc.$7.15 GURE

0.47+10.49%

Gulf Resources, Inc.$4.95

Company Overview

Balchem Corporation (NASDAQ:BCPC) closed at $180.29 USD, gaining $0.67 (0.37%) from the previous close of $179.62. The stock is currently within 5% of its 52-week high $139.17 and $183.01. With a market capitalization of about $5.84 billion, Balchem Corporation is classified as a mid-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 180.93 thousand shares, in line with its 52-week average. Headquartered in Montvale, NY, Balchem Corporation operates in the Basic Materials sector and the Chemicals - Specialty industry. Led by CEO Theodore Lee Harris, the company employs approximately 1,379 people and listed since June 03, 1986. Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 2.87%, SMA50 8.45%, SMA200 13.16%). The stock’s 14-day RSI is 63.78 (firm momentum), while the ATR of 4.59 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.49% below its high and over 29.55% above its low. Average 10-day trading volume of 173.48 thousand shares is in line with the 3-month average of 168.09 thousand, indicating normal recent market interest.

Valuation Metrics

Balchem Corporation trades at a P/E ratio of 37.77, slightly above the S&P 500 average, with a price-to-sales ratio of 5.65 and a price-to-book ratio of 4.65 trading at moderately above to book value. The P/FCF stands at 27.06, also above market averages.

Dividend & Fair Value

Balchem Corporation last paid a dividend of 0.96 per share, this equals a trailing yield of roughly 0.45%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $173.33. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

Balchem Corporation generated EPS of $4.75 over the past year. Five-year average earnings growth is 12.78%. The latest quarter delivered EPS of $1.23. The next quarter is forecast at $1.25. Next year's EPS is expected at $0.12. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $190.00 to $162.00. The high target offers 5.39% upside. The low target suggests -10.14% downside. The mean target is $182.75. This offers 1.36% upside. Balchem Corporation earnings surprise history is a mixed track record. The quarter that ended October 21, 2025, missed forecasts by -9.56%.

Shareholding & Insider Activity

Balchem Corporation has 32.39 million shares outstanding. The public float is 32.21 million shares, elevated short interest at 1.85% of float. This equals 435.28 thousand shares. The short ratio is 2.75 days. Institutional investors hold 91.27% of the float. Insiders own 0.37%. FITZPATRICK FRANK holds 73.19 thousand shares, Harris Theodore L has 66.41 thousand shares and TELEVANTOS JOHN Y has 28.33 thousand shares. Over the past six months, insider transactions show net selling. They sold 4.96 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Balchem generated $922.44M in revenue, or $28.43 per share. Gross margin was 32.75%, operating margin 19.31%, and net profit margin 11.77%. Returns are healthy, with ROA at 6.68% and ROE at 10.30%.
On valuation metrics, Balchem trades at a P/E of 37.77, P/S of 5.65 and P/B of 4.65. The current ratio is 2.07 and quick ratio is 1.33. Operationally, the company’s inventory turnover is 5.07 and cash conversion cycle is 89.43 days. Debt-to-equity is 0.15, supported by a cash flow-to-debt ratio of 1.13.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Balchem posted revenue of $922.44M, down slightly from $942.36M in the prior quarter. Gross profit was $302.06M (margin 32.75%). Operating income was $178.10M (margin 19.3%). Net income was$108.54M (EPS $3.38).
The company ended the quarter with $64.45M in cash and short-term investments, a total debt of $330.33M, and net debt of $265.89M. Total assets were $1.63B, with equity of $1.05B. Financials further reflected stability, with operating cash flow of $183.76M, free cash flow of $145.87M, and capital expenditures of - $37.89M.

Price Forecast & Outlook

Our AI price prediction model suggests that Balchem Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.31%, with price expected at $177.93 by March 11, 2026, within a range of $175.20 to $180.85 3-Month Outlook: Projected rise of 8.11%, reaching $194.91 by May 26, 2026, with a range of $183.37 to $204.76. 1-Year Outlook: Projected gain of 6.61%, with price at $192.21 by February 25, 2027, within a range of $188.29 to $197.06.

Key Takeaways

Balchem Corporation (NASDAQ:BCPC) shares are flat 6.68% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Balchem Corporation trading at a premium to the broader market with a P/E of 37.77. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $140.83, suggesting -21.89% downside. Our AI forecast model points to short-term weakness (-1.31% over two weeks), a medium-term rise (8.11% over three months), and a longer-term gain (6.61% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Balchem Corporation (BCPC) stock price?

Balchem Corporation (NASDAQ: BCPC) stock price is $180.29 in the last trading session. During the trading session, BCPC stock reached the peak price of $181.35 while $177.37 was the lowest point it dropped to. The percentage change in BCPC stock occurred in the recent session was 0.37% while the dollar amount for the price change in BCPC stock was $0.67.

BCPC's industry and sector of operation?

The NASDAQ listed BCPC is part of Chemicals - Specialty industry that operates in the broader Basic Materials sector. Balchem Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BCPC?

Mr. Mark A. Stach
Executive Officer
Mr. Jonathan Griffin
Senior Vice President and GM of Animal Nutrition & Health
Mr. Theodore L. Harris
Chairman, Chief Executive Officer & Pres
Mr. Frederic Boned
Senior Vice President and GM of Human Nutrition & Health
Mr. Brent Tignor
Senior Vice President & Chief HR Officer
Mr. Jonathan H. Griffin
Senior Vice President and GM of Animal Nutrition & Health
Mr. Martin Luther Reid
Senior Vice President & Chief Supply Chain Officer
Mr. Carl Martin Bengtsson
Executive Vice President, Chief Financial Officer & Treasurer
Ms. Hatsuki Miyata
Executive Vice President, Gen. Counsel & Corporation Sec.
Mr. William A. Backus C.P.A., CPA
Vice President & CAO
Mr. William A. Backus CPA, CPA
Vice President & CAO
Mr. Michael R. Sestrick Ph.D.
Senior Vice President & Chief Technology Officer
Mr. Job L. van Gunsteren
Senior Vice President & GM of Specialty Products

How BCPC did perform over past 52-week?

BCPC's closing price is 29.55% higher than its 52-week low of $139.17 where as its distance from 52-week high of $183.01 is -1.49%.

How many employees does BCPC have?

Number of BCPC employees currently stands at 1,379.

Link for BCPC official website?

Official Website of BCPC is: https://www.balchem.com

How do I contact BCPC?

BCPC could be contacted at phone 845 326 5600 and can also be accessed through its website. BCPC operates from 52 Sunrise Park Road, Montvale, NY 10958, United States.

How many shares of BCPC are traded daily?

BCPC stock volume for the day was 133.68K shares. The average number of BCPC shares traded daily for last 3 months was 180.93K.

What is the market cap of BCPC currently?

The market value of BCPC currently stands at $5.84B with its latest stock price at $180.29 and 32.39M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1379
Beta	0.95
Sales or Revenue	$922.44M
5Y Sales Change%	0.44%
Fiscal Year Ends	December
Sector	Basic Materials
Industry	Chemicals - Specialty

BCPC Company Profile and Key Details

Balchem

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways